This gene encodes a G-protein coupled receptor that binds neuropeptides of the corticotropin releasing hormone family that are major regulators of the hypothalamic-pituitary-adrenal pathway. The encoded protein is essential for the activation of signal transduction pathways that regulate diverse physiological processes including stress, reproduction, immune response and obesity. Alternative splicing results in multiple transcript variants, one of which represents a read-through transcript with the neighboring gene MGC57346. [provided by RefSeq, Jan 2012] (from
Nunes-de-Souza et al., São Carlos, Brazil. In Horm Behav, Feb 2016
The role of CRFergic and glutamatergic systems on defensive behavior induced by NOC-9 was investigated with previous intra-BNST infusion of different doses of CP376395, a CRF type 1 receptor antagonist (CRF1), or AP-7, an NMDA (N-methyl-d-aspartate) receptor antagonist.
Auchus et al., San Diego, United States. In J Clin Endocrinol Metab, Feb 2016
OBJECTIVES: We evaluated the safety and tolerability of the selective corticotropin releasing factor type 1 (CRF1) receptor antagonist NBI-77860 in women with classic 21OHD and tested the hypothesis that CRF1 receptor blockade decreases early morning ACTH and 17α-hydroxyprogesterone (17OHP) in these patients.
Domschke et al., Würzburg, Germany. In Curr Opin Psychiatry, Jan 2016
Similar multi-level results have been reported for genetic and epigenetic variation in the OXTR gene, especially in social anxiety disorder (SAD), and for CRHR1 gene variation in women with panic disorder.
Rissman et al., San Diego, United States. In Plos One, Dec 2015
UNASSIGNED: Stress exposure or increased levels of corticotropin-releasing factor (CRF) induce hippocampal tau phosphorylation (tau-P) in rodent models, a process that is dependent on the type-1 CRF receptor (CRFR1).
Summers et al., Fredericksburg, United States. In Neurosci Biobehav Rev, Nov 2015
Recent clinical and preclinical studies, using genetic screening and transgenic rodents, respectively, suggest a major role of the CRF1 gene, and the central expression of CRF1 receptor protein in determining an individual's risk of developing MDD.
Okumura et al., Asahikawa, Japan. In J Gastroenterol, Aug 2015
CRF in brain and periphery acts through two subtype receptors such as CRF receptor type 1 (CRF1) and type 2 (CRF2), and activating CRF1 exclusively stimulates colonic motor function and induces visceral hypersensitivity.
Zangrossi et al., Ribeirão Preto, Brazil. In Cns Neurol Disord Drug Targets, 2014
On the other hand, facilitation of corticotrophin releasing factor- or cholecystokinin-mediated neurotransmission in the DPAG, via CRF1 and CCK2 receptors, respectively, causes panicogenic-like effects with implications for the pathogenesis of PD.
Phillips et al., Seattle, United States. In Nature, 2012
Here we report that corticotropin-releasing factor (CRF), a neuropeptide released in response to acute stressors and other arousing environmental stimuli, acts in the nucleus accumbens of naive mice to increase dopamine release through coactivation of the receptors CRFR1 and CRFR2.
Sherman et al., Atlanta, United States. In Am J Med Genet B Neuropsychiatr Genet, 2012
Genetic variants in CRHR1 that associate with differential cortisol activation may also modulate levels of anxiety related to the stress of raising a child with fragile X syndrome among women who carry an FMR1 premutation.
Deussing et al., München, Germany. In Science, 2011
results define a bidirectional model for the role of CRHR1 in anxiety and suggest that an imbalance between CRHR1-controlled anxiogenic glutamatergic and anxiolytic dopaminergic systems might lead to emotional disorders